Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

Next Catalyst for Treasury Bonds Is Named Kevin Warsh

View original at finance.yahoo.com
Next Catalyst for Treasury Bonds Is Named Kevin Warsh (Bloomberg) -- Bond traders who’ve grown more optimistic about an end to the Iran conflict see their next catalyst coming from Capitol Hill, where Kevin Warsh will face questions as President Donald Trump’s pick to lead the Federal Reserve…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The big move Friday was justified because the rates market was still pricing in higher energy prices amid an above target inflation backdrop which would constrain the Fed

    60% confidence
  • Iran will suspend nuclear program as Hormuz opens

    60% confidence
  • New Iran talks to seek end of Hormuz standoff

    60% confidence
  • A key question for markets is how heavily Warsh will advocate rate cuts

    60% confidence
  • If oil prices continue to fall, the market can start pricing in gradual Fed rate cuts

    60% confidence
  • Kevin Warsh voiced support for lower interest rates before gaining Trump's nomination

    60% confidence

Data points we hold from this source

Board of Governors of the Federal Reserve System · interest rate ceiling3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com